Cargando…
Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report
Prader-Willi syndrome (PWS) is often related to severe obesity and diabetes mellitus (DM). Clinical findings suggesting the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists for glycemic control of DM in PWS have been recently increasing. However, there are only a few reports describing...
Autores principales: | Sano, Hitomi, Kudo, Eriko, Yamazaki, Takeshi, Ito, Tomoshiro, Hatakeyama, Kinya, Kawamura, Nobuaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society for Pediatric Endocrinology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160459/ https://www.ncbi.nlm.nih.gov/pubmed/32313377 http://dx.doi.org/10.1297/cpe.29.81 |
Ejemplares similares
-
Posterior reversible encephalopathy syndrome associated with mild COVID-19 infection in a 9-year-old child: A case report and literature review
por: Sano, Hitomi, et al.
Publicado: (2023) -
Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader–Willi Syndrome: A Case Report
por: Horikawa, Yukio, et al.
Publicado: (2018) -
Glucagon stimulation test to assess growth hormone status in Prader–Willi syndrome
por: Casamitjana, L., et al.
Publicado: (2020) -
Three Siblings with Prader-Willi Syndrome: Brief Review of Sleep and Prader-Willi Syndrome
por: Bingeliene, Arina, et al.
Publicado: (2015) -
Genetics of Prader-Willi syndrome and Prader-Will-Like syndrome
por: Cheon, Chong Kun
Publicado: (2016)